



Jan. 7, 2020

PRESS RELEASE

Company: RaQualia Pharma Inc.

(Ticker code: 4579)

Representative: Representative Director Naoki Tani

Inquiries: Executive Vice President Kiichiro Kawada

(TEL. +81-52-446-6100)

5-HT₄ Partial Agonist Use Patent Allowance in Europe

January 7, 2020 - RaQualia Pharma Inc. (RaQualia) today announced that the company received an allowance* for a 5-HT₄ partial agonist use patent in Europe (Application Number: 15793503.2). In addition to the allowance of use patent on gastroparesis received in the U.S.A., this allowance ensures that the company's intellectual property rights will be strengthened in Europe.

The serotonin 5-HT₄ receptor is known to play an important role in regulating gastrointestinal motility. The patented compound has been confirmed to accelerate gastric emptying and has fewer of the cardiovascular adverse events, while conventional 5-HT₄ receptor agonists have the problem of showing cardiovascular side effects. Therefore, the 5-HT₄ partial agonist is expected to be a useful drug for the treatment of gastroparesis with high safety.

RaQualia will continue to promote its licensing activities for 5-HT₄ partial agonist globally.

The financial forecasts for the fiscal year 2020 (Jan. 1, 2020 – Dec. 31, 2020) will not be affected by this announcement.

*A patent allowance is an evaluation by a country's patent office that a patent application merits being granted a patent. After the patent is allowed and the fee paid, it is registered and the patent is issued in the relevant country.

End